As of 2008 there were more than 400<unk>  trials underway to understand and treat Alzheimer's<unk> . Over one hundred of these studies were in the last phase before commercialization (phase three trials).
Many different investigation approaches coexist. Amyloid beta is a common target, existing many trials which aim to reduce it with different agents such as bapineuzumab, an antibody in phase III for patients in the mild to moderate stage, MPC-7869, or acc-001, a vaccine to amyloid beta in phase II to be used in the mild stage. Other approaches are neuroprotective agents, like AL-108 (phase II completed); or metal-protein interaction attenuation, as is the case of PBT2 (phase II completed). Finally, there are also many basic investigations trying to increase the knowledge on the origin and mechanisms of the<unk>  that in the future may help to find new treatments.
Alzheimer's disease clinical research
Alzheimer's disease future or investigational therapies
Delirium cost-effectiveness of therapy
Ischemic stroke early assessment
Beriberi primary prevention
Beriberi secondary prevention
Traumatic brain injury cost-effectiveness of therapy
Multiple sclerosis cost-effectiveness of therapy